肿瘤标志物检测在非小细胞肺癌放化疗中的临床意义
Clinical significance of tumor markers in combined treatment of radiotherapy and chemotherapy for non-small-cell lung cancer
陈梅 1周静 1陈绪元2
作者信息
- 1. 荆楚理工学院医学院病理学教研室,湖北,荆门,448000
- 2. 重庆医科大学附属第一医院肿瘤科,重庆,400016
- 折叠
摘要
目的:观察肿瘤标志物在非小细胞肺癌(NSCLC)后程超分割放疗同步化疗中的变化,评价以上肿瘤标志物的临床价值.方法:43例NSCLC患者均进行后程逐量加速超分割照射(LCEHART)同步两周期化疗,分别于治疗前以及治疗完成后3 wk进行肿瘤特异性生长因子(TSGF)以及多肿瘤标志物蛋白芯片检测.结果:TSGF,Ft,CA125在治疗开始时的阳性率分别为67%,53%,55%,治疗后所观测指标中TSGF和CA125有显著性下降(P<0.05),尤其对于达CR的患者.在治疗有效的患者中,CA125阴性患者的近期生存期显著长于阳性患者.结论:NSCLC患者LCEHART同步NP方案化疗中,对于治疗有效患者,TSGF,CA125的下降与影像学资料具有一致性;并且CA125可以作为预后指标.
Abstract
AIM: To observe the changes of TSGF, Ft and CA125 in non-small-cell lung cancer (NSCLC) treated by late-course escalated hyperfractionated accelerated radiotherapy (LCEHART) combined with chemotherapy and to evaluate the clinical significance of the above tumor makers. METHODS: Forty-three NSCLC patients were treated by LCEHART combined with two-cycle chemotherapy, and TSGF and multi-tumor maker protein chip were detected before and 3 weeks after therapy. RESULTS: The positive rate of TSGF, Ft and CA125 was respectively 67%, 53% and 55% before the treatment. After treatment, significant decrease was observed in TSGF and CA125 (P ＜ 0.05), especially in patients of complete response (CR). Patients of CR and partial response (PR) with negative CA125 expression had longer recent survival time compared with the patients with positive expression (P ＜ 0.05). CONCLUSION: In NSCLC patients who are effectively treated by LCEHART combined with NP chemotherapy, the decrease of TSGF and CA125 is consistent to the imaging changes. CA125 thus can be used as a prognosis index.
关键词
肺肿瘤/肿瘤标记,生物学/蛋白芯片/放射疗法/药物疗法Key words
lung neoplasms/tumor markers, biological/protein chip/radiotherapy/drug therapy引用本文复制引用
基金项目
荆门市科技基金(荆科技20086号/08S19)
出版年
2009
NETL
NSTL
维普
万方数据